UTHR (United Therapeutics) NonCurrent Deferred Liabilities: $0 Mil (As of Mar. 2026)


UTHR United Therapeutics Corp UTHR
85 GF Score
Price $552.19
GF Value $386.91
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics NonCurrent Deferred Liabilities?

United Therapeutics UTHR -0.39% 85 NonCurrent Deferred Liabilities is $0 Mil as of Mar. 2026. GuruFocus rates UTHR with a GF Score™ of 85/100 and a GF Value™ of $386.91 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

United Therapeutics's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $0 Mil.

United Therapeutics NonCurrent Deferred Liabilities Related Terms

United Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for United Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics NonCurrent Deferred Liabilities Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

United Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
UTHR
85GF Score
United Therapeutics Corp UTHR
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0 Mil mean?
United Therapeutics (UTHR) has a NonCurrent Deferred Liabilities of $0 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' NonCurrent Deferred Liabilities too high?
United Therapeutics' current NonCurrent Deferred Liabilities is $0 Mil. Overall, United Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' NonCurrent Deferred Liabilities compare to VTRS and NBIX?
United Therapeutics' NonCurrent Deferred Liabilities of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on United Therapeutics and its competitors. United Therapeutics's current NonCurrent Deferred Liabilities is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.91, compared to a current price of $552.19 — trading 42.7% above its estimated fair value. The current NonCurrent Deferred Liabilities is $0 Mil. United Therapeutics' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For United Therapeutics (UTHR), the current NonCurrent Deferred Liabilities is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $552.19 is trading 42.7% above its estimated GF Value™ of $386.91. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for UTHR:

  • NonCurrent Deferred Liabilities: $0 Mil
  • GF Value™: $386.91 vs. price of $552.19 (42.7% above fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTH:GermanyU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
85GF Score

Get the complete analysis for UTHR

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$552.19
Price
$386.91
GF Value